Asia Fresh News

Asia Fresh Stories

Posts Tagged ‘Medical/Healthcare

Memorandum of Agreement: Training State Regulators to Advance the Quality of Orthopaedic Care for China

leave a comment »

BEIJING /PRNewswire/ — Zimmer Holdings, Inc. (NYSE: ZMH; SIX: ZMH), a global leader in musculoskeletal health, today signed a Memorandum of Agreement with the Beijing Drug Administration (BJDA) to jointly hold training sessions at Montagne, Zimmer’s wholly-owned Chinese subsidiary. The trainings will be dedicated to the mutual sharing of knowledge and expertise in research, development, quality and regulation related to musculoskeletal health. The partnership aims to allow BJDA to gain industry knowledge and to understand Zimmer and its products through dialogues and trainings undertaken by its State Inspectors. The goal of the agreement also includes strengthening production and inspection expertise at Chinese medical device companies to ensure the delivery of safe and quality orthopaedic medical devices.
Under the terms of the Agreement, which is a first with the Chinese government for Zimmer, BJDA will provide the Company with professional training regarding Chinese laws and regulations related to the manufacture and sale of medical devices. Zimmer, in turn, will share proven experience in areas including research, development, inspection, clinical use and quality systems management. The Company is recognized internationally for the quality of its professional education training provided to surgeons through the Zimmer Institute.
“This collaboration with the Beijing Drug Administration marks a new milestone for Zimmer in China. Worldwide, Zimmer is a recognized leader in the development of products, services and professional training that helps patients overcome pain and regain mobility,” said David Dvorak, President and CEO of Zimmer. “Cooperating with BJDA, we are strengthening our commitment to the Chinese market. The knowledge and expertise Zimmer’s employees and the State Regulators will share with one another will help to elevate orthopaedic medicine in China.”
“Beijing Drug Administration is pleased that Zimmer is cooperating with us in this initiative,” said Ms. Lu Aili, Deputy Director General of Beijing Drug Administration.
“The trainings provide a platform by which both sides will be able to gain from each other’s strengths related to medical devices, especially in the area of orthopaedic reconstructive. Overall, BJDA is committed to working with all our partners and industry stakeholders to achieve the goals set forth in the 12th Five-Year Plan of upgrading the healthcare industry and ensuring citizens’ health and quality of life.”
China is among the fast-growing emerging markets for medical devices, with high unmet needs in the treatment of musculoskeletal diseases, including arthritis. Primarily associated with the elderly, arthritis is on the rise as China’s population ages. According to recently released statistics by the China National Committee on Aging, the number of Chinese senior citizens is expected to increase from the current 185 million to 487 million, or 35 percent of the population, by 2053.
This joint effort by Zimmer and the BJDA to hold training sessions lays the groundwork for additional opportunities to share knowledge in the near future. This collaboration will further enhance the safety and effectiveness of medical devices, provide musculoskeletal health solutions and improve the quality of life for patients in China.
About the Company

Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer designs, develops, manufactures and markets orthopaedic reconstructive, spinal and trauma devices, dental implants, and related surgical products. Zimmer has operations in more than 25 countries around the world and sells products in more than 100 countries. Zimmer’s 2011 sales were approximately $4.5 billion. The Company is supported by the efforts of more than 9,000 employees worldwide.
For more information, please visit our website at http://www.zimmer.com.
Source: Zimmer Holdings, Inc.

Written by asiafreshnews

November 16, 2012 at 3:18 pm

Posted in Uncategorized

Tagged with

National Foundation for Cancer Research and the Chinese Academy of Medical Sciences Host U.S.-China Symposium on State-of-Science Cancer Research and Future Direction for Global Collaboration

leave a comment »

BETHESDA, Md. /PRNewswire/ — The National Foundation for Cancer Research (NFCR) and the Chinese Academy of Medical Sciences (CAMS) today announced that they will co-host a high-level symposium in Beijing November 4-6, 2012.
The U.S.-China Symposium on State-of-Science Cancer Research and Future Directions for Global Collaboration will bring together leading cancer researchers from the United States and China in an attempt to launch an actionable roadmap for international research collaboration that will accelerate innovative cancer research and discovery.
Leading cancer researchers from both academia and industry in China and the U.S. are committed to working together to create a platform of global collaboration for cancer drug-discovery and development.
This Symposium will be a transformative opportunity for shaping the future direction of cancer research in the U.S. and China. “Through stronger partnerships with our scientific and corporate colleagues in the United States, we hope to advance our efforts to build a more effective research platform for government and industry toward shared progress in research to cure cancer,” said Dr. Xuetao Cao, President of the Chinese Academy of Medical Sciences and co-host of the Symposium.
The topics addressed at this Symposium will help build bridges between and among cancer researchers regardless of field or national boundaries. “Developing action plans that foster global collaboration in cancer research will both accelerate scientific discoveries and their development into new therapies,” said Franklin Salisbury, Jr. President of the National Foundation for Cancer Research and co-host of the Symposium.
“We salute this type of synergistic collaboration across international borders, and are pleased to be a part of this Symposium,” said Dr. Sujuan Ba, President of the Asian Fund for Cancer Research and sponsor. Other sponsors include: AstraZeneca, Eli Lilly, and Cancer Institute & Hospital Chinese Academy of Medical Sciences.
Symposium Speakers and Format
The two-day Symposium will bring together prominent cancer researchers from government, academia, and industry to create a platform for global collaboration in cancer research that will foster scientific innovation and discovery.
A Plenary Session will feature Chinese Minister of Health Zhu Chen, M.D., Ph.D, and Anna Barker, Ph.D, Director, Arizona State University Transformative Healthcare Networks and former Deputy Director of the U.S. National Cancer Institute (NCI).
Other leading scientists participating in the Symposium include:
Steven Averbuch M.D., Bristol Myers Squibb
Anahita Bhathena, Ph.D., Abbott Laboratories
Xuetao Cao, M.D, Ph.D., Chinese Academy of Medical Sciences
Webster Cavenee, Ph.D., Ludwig Institute for Cancer Research
Shujun Cheng, M.D., Cancer Institute & Hospital Chinese Academy of Medical Sciences
Yung-Chi Cheng, Ph.D., Yale University Medical School
Carlo Croce, M.D., Ohio State University Medical Center
Jianren Gu, M.D., Ph.D., Shanghai Cancer Institute, Shanghai Jiao Tong University
Xi-Shan Hao, M.D., Chinese Anti-Cancer Association; Tianjin Medical University Cancer Institute
Waun Ki Hong, M.D., MD Anderson Cancer Center
Susan Horwitz, Ph.D., Albert Einstein College of Medicine
Scott Patterson, Ph.D., Amgen
George Sledge, Jr., Ph.D., Indiana University School of Medicine
Yan Sun, M.D., Cancer Institute & Hospital Chinese Academy of Medical Sciences
Zhaoyou Tang, M.D., Liver Cancer Institute, Fudan University
Peter Vogt, Ph.D., The Scripps Research Institute
Qimin Zhan, M.D., Chinese Academy of Medical Sciences
Symposium Topics will include:
Pathway for New Therapy Development in China and Vision for International Collaboration
Global Clinical Development Networks: 21st Century Approach to Clinical Trials
Biobanking and its Critical Role in Translational Cancer Research
Traditional Chinese Medicines and Natural Products: New Paradigm for Treating Cancer
Biomarkers and Molecular Medicines
Cancer Genome: Developing Genetic-Based Cancer Therapies
A Collaborative Initiative to Conquer GBM—A Model for International Collaboration
For a complete Symposium Program, and to see the full list of speakers, visit http://www.NFCR.org/symposium.
This Symposium is open by invitation and to accredited media. Journalists are encouraged to register with Silas Deane at (01) 615-319-6007 or sdeane@nfcr.org.
About the National Foundation for Cancer Research
The National Foundation for Cancer Research is a leading charity dedicated to funding innovative cancer research worldwide. NFCR promotes and facilitates collaboration among scientists to accelerate the pace of discovery, and since 1973 NFCR has spent over $300 million funding the “high risk/high reward” research responsible for many breakthroughs in cancer research. NFCR is committed to solving cancer’s molecular mysteries, and translating these discoveries into new approaches to preventing, diagnosing and treating cancer. NFCR is about Research for a Cure—cures for all types of cancer. For more information, please visit http://www.NFCR.org.
About the Chinese Academy of Medical Sciences
The Chinese Academy of Medical Sciences (CAMS) is the most important medical institution in China and is directly under the leadership of the Ministry of Health. The CAMS was created in 1956 by the Chinese government and was merged with Peking Union Medical College (PUMC) in Beijing. The mission of CAMS is to encourage high-quality research in biomedical science with the aim of improving people’s health and reducing the death rate, to offer the best clinical diagnoses and treatments for severe and rare diseases, to promote the transition of research to clinical applications, and to train first-rate medical professionals for research, clinical applications, and education. For more information, please visit, http://www.CAMS.ac.cn.
About the Asian Fund for Cancer Research
The Asian Fund for Cancer Research (AFCR) is committed to curing cancers that have significant impacts on Asian populations. Headquartered in Hong Kong, AFCR is dedicated to bridging the scientific and educational gaps in cancer research and cancer prevention between Asian countries and the rest of the world, through promoting, coordinating and funding international collaboration in cancer research and public education. AFCR is devoted to reducing the incidence and increasing the survival rate of cancers in Asia. For more information, please visit http://www.AFCR.org.hk.
Media Contact: Silas Deane
(01) 615-319-6007
sdeane@nfcr.org
Source: National Foundation for Cancer Research

Written by asiafreshnews

November 5, 2012 at 11:06 am

Posted in Uncategorized

Tagged with

University Of Maryland Patient Exceeding Expectations Seven Months After Most Extensive Face Transplant Ever Performed

leave a comment »

— Richard Lee Norris returning to normal life after 15 years as recluse
BALTIMORE/PRNewswire/ — The University of Maryland released details today on the recovery of Richard Lee Norris, the 37-year-old man who received the most extensive full face transplant completed to date seven months ago. Norris, of Hillsville, Virginia, was injured in a 1997 gun accident, losing much of his upper and lower jaws as well as his lips and nose. The transplant surgery, completed on March 20, 2012 at the University of Maryland Medical Center, included replacement of both jaws, teeth, tongue, and skin and underlying nerve and muscle tissue from scalp to neck.
“For the past 15 years I lived as a recluse hiding behind a surgical mask and doing most of my shopping at night when less people were around,” says Norris. “I can now go out and not get the stares and have to hear comments that people would make. People used to stare at me because of my disfigurement. Now they can stare at me in amazement and in the transformation I have taken. I am now able to walk past people and no one even gives me a second look. My friends have moved on with their lives, starting families and careers. I can now start working on the new life given back to me.”
“I am doing well. I spend a lot of my time fishing and working on my golf game. I am also enjoying time with my family and friends,” says Norris. “I do still have follow-up appointments with a lot of different doctors and therapists to ensure everything is healing up properly. I have been undergoing physical therapy and also speech therapy. I have been doing very well regaining my speech back. Each day it improves a little more.”
Norris continues to gain sensation in his face and is able to smile and show expression. His doctors say the motor function on the right side of his face is about 80 percent normal, and motor function on the left side is about 40 percent. He eats primarily by mouth and is able to smell and taste.
Norris’ historic 36-hour full face transplant was led by Eduardo D. Rodriguez, M.D., D.D.S., professor of surgery at the University of Maryland School of Medicine and chief of plastic, reconstructive and maxillofacial surgery at the R Adams Cowley Shock Trauma Center at the University of Maryland Medical Center. Norris’ surgery marked the first time in the world that a face transplant was performed by a team of plastic and reconstructive surgeons with specialized training and expertise in craniofacial surgery and reconstructive microsurgery.
About the University of Maryland School of Medicine, University of Maryland Medical Center & R Adams Cowley Shock Trauma Center
Founded in 1807, the University of Maryland School of Medicine in Baltimore is the oldest public medical school in the United States, and the first to institute a residency training program. The School of Medicine was the founding school of the University of Maryland and today is an integral part of the 11-campus University System of Maryland. The partnership between the University of Maryland Medical Center (UMMC) and the University of Maryland School of Medicine allows cutting edge medical research and discovery to rapidly innovate and improve patient care and prepare the next generation of health care professionals through excellent training and education.
The University of Maryland Medical Center (UMMC) is a 779-bed teaching hospital in Baltimore and the flagship institution of the 11-hospital University of Maryland Medical System. Patients are referred nationally and regionally for advanced medical, surgical and critical care. All physicians on staff at the Medical Center are faculty physicians of the University of Maryland School of Medicine.
The R Adams Cowley Shock Trauma Center at the University of Maryland Medical Center is the nation’s first coordinated trauma system and is dedicated to multidisciplinary research and treatment of critical injury and illness. Shock Trauma is where the “golden hour” concept in critical care medicine was born. Under the direction of Thomas M. Scalea, M.D, Shock Trauma treats more than 8,000 trauma and critical care patients each year and trains trauma providers from around the world including U.S. military medical professionals.
Source: University of Maryland Medical Center

Written by asiafreshnews

October 18, 2012 at 11:15 am

Posted in Uncategorized

Tagged with

ChanTest Announces Drug Discovery Services Using the Enamine 3D Compound Library

leave a comment »

CLEVELAND /PRNewswire/ — ChanTest, the industry leading ion channel Contract Research Organization (CRO) announces today the addition of a 50,000 compound chemical library from Enamine Ltd., a leading provider of screening compounds and chemical building blocks. This compound library (3D Diversity Set) will be available to ChanTest clients effective immediately as a key tool for drug discovery services.
(Logo: http://photos.prnewswire.com/prnh/20120817/CL58977LOGO )
Enamine created this 3D Diversity Set of compounds by selecting from their 1.6 million compound high throughput screening collection (HTS collection) based on the diversity of three dimensional shapes. All compounds in the HTS collection are “drug-like” according to Lipinski Rules, so compounds in the 3D Diversity Set have maximum diversity based on molecular shape and structural/physiochemical features common to known drugs.
Bill Heilman, Business Development Director, at Enamine, said, “We are excited about partnering with ChanTest. Our company and reputation grows among professional screening companies and academic research centers as more research programs screen our compounds in various assays.”
ChanTest offers screening of the Enamine 3D Diversity Set to clients outsourcing drug discovery screening programs to ChanTest. ChanTest has the broadest selection of ion channel assays-and industry-leading expertise to match. Included with each drug discovery service contract, ChanTest scientists work with clients to design meaningful assays and interpret the results in a cost effective manner. In this case, ChanTest and Enamine will partner with clients to convert hits identified from the non-proprietary library to proprietary leads.
Chris Mathes, Ph.D., Chief Commercial Officer at ChanTest commented, “Discovery services at ChanTest lacked a large compound library for high throughput screening. Thanks to the 3D Diversity Set from Enamine, ChanTest can now use its powerful HTS of Ion Channels, GPCRs and Transporters in partnership with pharma and biotech companies to help discover new drugs.”
About ChanTest — The Ion Channel Expert
ChanTest’s mission is to serve the drug discovery and development needs of customers worldwide with high-value solutions for ion channel and GPCR biology. Since its inception in 1998, the CRO has tested compounds for more than 500 global pharmaceutical and biotechnology companies and partners with them to speed the drug development process for the release of better, safer drugs. ChanTest offers integrated ion channel and GPCR services (GLP and non-GLP) and reagents; the company’s library of validated ion channel cell lines and pre-clinical cardiac risk assessment service portfolio are the most comprehensive commercially available today. Because of ChanTest’s seminal role in the nonclinical cardiac safety field, along with the company’s uncompromising commitment to quality, ChanTest has been named the “most trusted and most used fee-for-service provider” for ion channel screening in an independent survey for the past three years. ChanTest is based in Cleveland, Ohio. For more information, e-mail info@chantest.com.
About Enamine
Established in Kiev in 1991, Enamine, Ltd. is a chemical company supplying novel screening compounds to the pharmaceutical, cosmetic, nutritional and agrochemical industries. Enamine’s design and synthesis capabilities allow the Company to add more than 250,000 new organic compounds to its catalogue of screening compounds each year, with 2 million compounds currently available. These compounds can be downloaded from their web site at: http://www.enamine.net. The Company offers collaborative expertise to exclusively design and supply libraries of new, potentially bioactive organic compounds and building blocks, in addition to furnishing in-house chemical libraries to screening centers worldwide.
Contact:
Chris Mathes, Ph.D.
Chief Commercial Officer
ChanTest Corporation
1-216-584-0522
cmathes@chantest.com
Source: ChanTest Corporation

Written by asiafreshnews

October 16, 2012 at 10:30 am

Posted in Uncategorized

Tagged with